Clinical trials
Observational Thrombocythemia, Essential trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Icahn School of Medicine at Mount Sinai | 3 |
| Shire | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 1 |
| Federico II University | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Thrombocythemia, Essential | 12 |
| Polycythemia Vera | 8 |
| Primary Myelofibrosis | 8 |
| Myeloproliferative Disorders | 5 |
| Blast Crisis | 1 |
| Breast Carcinoma In Situ | 1 |
| Breast Neoplasms | 1 |
| Breast Neoplasms, Male | 1 |
| Burkitt Lymphoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.